Actelion’s Uptravi will not be funded on the NHS for patients with Pulmonary Arterial Hypertension (PAH), after the drug failed to make it into NHS England’s latest round of specialised commissioning approvals.
Read More
Some patients with pulmonary arterial hypertension (PAH) are now able to access Actelion’s selexipag on the NHS in Wales after a green light from the All Wales Medicines Strategy Group (AWMSG).
Read More
A new treatment option for the very rare condition infantile onset 5q spinal muscular atrophy (type I SMA) is among five medicines that have been endorsed by Scottish cost regulators for use on the NHS.
Read More
Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.
Read More
European regulators have ruled that Actelion’s Uptravi can continue to be used as per its prescribing information to treat patients with pulmonary arterial hypertension, a life-threatening condition involving abnormally high blood pressure in the arteries of the lungs.
Read More
European regulators are advising that doctors can continue prescribing Actelion’s Uptravi for pulmonary arterial hypertension while an investigation into its safety is completed.
Read More
EU regulators have issued a green light for Actelion’s Uptravi, offering a new treatment option to patients with pulmonary arterial hypertension.
Read More
